South and Central America Monoclonal Antibodies Market
No. of Pages: 151 | Report Code: TIPRE00028629 | Category: Life Sciences
No. of Pages: 151 | Report Code: TIPRE00028629 | Category: Life Sciences
According to the NCBI report, monoclonal antibodies (mABs) have been considered as an innovative technology for the treatment of some types of cancer, as they possess the capability of targeting and selectively killing tumor cells. For example, there was a retrospective analysis conducted based on consultation of the Brazilian Health Regulatory Agency (Anvisa) where these mABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant. For records, in August 2021, Anvisa announced granting of emergency use authorization (EUA) for Celltrion’s “Regdanvimab (CT-P59)” for treating adults with mild-to-moderate COVID-19 and who do not require supplemental oxygen and are at higher risk of progression to severe COVID. As Brazil had the highest number of confirmed cases from COVID-19 in South and Central America with an average 35,000 cases per day and since the beginning of pandemic, at least 1 in 10 residents have been infected a total of 20,249,176 reported severe cases. Therefore, Celltrion’s monoclonal antibody-based product significantly reduces the risk of COVID-19 related hospitalization and deaths by 72% for patients at higher risk of progression to severe COVID-19 and 70% of all patients. Therefore, amid COVID-19 pandemic, monoclonal antibodies witnessed highest ever adoption in South and Central America regional market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The South & Central America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
Strategic insights for the South and Central America Monoclonal Antibodies provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 5,584.2 Million |
| Market Size by 2028 | US$ 10,847.3 Million |
| Global CAGR (2021 - 2028) | 9.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Source
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
The geographic scope of the South and Central America Monoclonal Antibodies refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The South and Central America Monoclonal Antibodies Market is valued at US$ 5,584.2 Million in 2021, it is projected to reach US$ 10,847.3 Million by 2028.
As per our report South and Central America Monoclonal Antibodies Market, the market size is valued at US$ 5,584.2 Million in 2021, projecting it to reach US$ 10,847.3 Million by 2028. This translates to a CAGR of approximately 9.9% during the forecast period.
The South and Central America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Monoclonal Antibodies Market report:
The South and Central America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Monoclonal Antibodies Market
